F-group (family)
5.1.4.13 FG-GAP
Ligands and drugs
179
Member domains
92
with ligand contacts (≤ 4 Å)
51.4% of members
69
with DrugDomain annotations
38.5% of members
67
with a DrugBank compound
37.4% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 5.1.4.13 belongs to X-group 5 beta-propeller-like, which binds 7.8 ligand superclasses per 20 proteins, broader than 52% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 65 |
| DB00451 | — | Levothyroxine | 1 |
| DB02709 | — | Resveratrol | 1 |
| DB08834 | — | Tauroursodeoxycholic acid | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CAmetal | CALCIUM ION | 73 |
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 39 |
| MNmetal | MANGANESE (II) ION | 13 |
| CL | CHLORIDE ION | 5 |
| MGmetal | MAGNESIUM ION | 4 |
| A1D8D | (2~{S})-3-[2-azanylethanoyl-[3-oxidanyl-5-[(5-oxidanylpyrimidin-2-yl)amino]phenyl]carbonyl-amino]-2-(3-bromanyl-5-~{tert}-butyl-phenyl)propanoic acid | 2 |
| A1LU4 | 2-[(2~{R},5~{R},8~{S},11~{S})-11-(3-carbamimidamidopropyl)-7-methyl-3,6,9,12,15-pentakis(oxidanylidene)-5-(phenylmethyl)-8-propan-2-yl-1,4,7,10,13-pentazacyclopentadec-2-yl]ethanoic acid | 2 |
| A1LU7 | 2-[(2~{R},5~{R},8~{S},11~{S})-8-(4-azanylbutyl)-11-(3-carbamimidamidopropyl)-3,6,9,12,15-pentakis(oxidanylidene)-5-(phenylmethyl)-1,4,7,10,13-pentazacyclopentadec-2-yl]ethanoic acid | 2 |
| MAN | alpha-D-mannopyranose | 2 |
| A1A6A | (2S)-phenyl{(3S)-3-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]pyrrolidin-1-yl}acetic acid | 1 |
| A1A6B | (2S)-(2-cyclopropylphenyl){(3R)-3-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]pyrrolidin-1-yl}acetic acid | 1 |
| A1A6H | (2S)-{5-fluoro-2-[(2S)-oxan-2-yl]phenyl}{(3R)-3-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]pyrrolidin-1-yl}acetic acid | 1 |
| A1A6I | (2S)-{5-fluoro-2-[(6S)-5-oxaspiro[2.5]octan-6-yl]phenyl}{(3R)-3-[4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butoxy]pyrrolidin-1-yl}acetic acid | 1 |
| A1AFA | N-(2,4-dichlorobenzoyl)-L-phenylalanine | 1 |
| JUY | (2S)-2-[(1,3-benzothiazole-2-carbonyl)amino]-4-{[5-(1,8-naphthyridin-2-yl)pentanoyl]amino}butanoic acid | 1 |
| NAmetal | SODIUM ION | 1 |
| NImetal | NICKEL (II) ION | 1 |